Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has scheduled a conference call with analysts/investors to discuss its unaudited financial results for Q2FY27, to be held on October 16, 2026, at 4:00 pm IST.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has received an ESG rating of Crisil ESG 63 under the Strong category from Crisil ESG Ratings & Analytics Limited for Fiscal 2026. The rating is an upgrade from Crisil ESG 56 for the period ended March 31, 2025.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has approved the issuance of a fresh Final Reminder-cum-Forfeiture Notice to partly paid-up Rights Equity Shareholders who have not paid the outstanding First Call Money and/or Second and Final Call Money.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 16/10/2026 to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30, 2026.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has issued a reminder to shareholders holding physical shares to furnish their PAN, KYC details, and nomination by September 26, 2026, as per SEBI's Master Circular HO/38/13/(4)2026-MIRSD-POD/I/4298/2026.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its financial results for the quarter and half year ending September 30, 2026.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has announced the voting results and scrutinizer's report of its Ninth Annual General Meeting, where all resolutions were passed with requisite majority.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has received a Rectification Order from the Assistant Commissioner of Income Tax, Central Circle 3, Thane, rectifying the error in tax computation and dropping the tax demand of Rs. 161.92 Crores raised pursuant to the Demand Notice received on March 17, 2026.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has published a newspaper advertisement regarding the completion of dispatch of 9th AGM Notice and Annual Report, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has released its Business Responsibility and Sustainability Report for the financial year 2025-26, as per SEBI regulations.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has announced its Annual Report for the financial year ended March 31, 2026, and has scheduled its Ninth Annual General Meeting (AGM) to be held on September 18, 2026, through Video Conference (VC) / Other Audio-Visual Means (OAVM).

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has announced the dispatch of Notice of Ninth Annual General Meeting (AGM) scheduled to be held on September 18, 2026, to consider and adopt the Audited Standalone Financial Statements for the financial year ended March 31, 2026, and other business.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has informed the stock exchange regarding the Newspaper publication with respect to the Ninth Annual General Meeting.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has converted partly paid-up Rights Equity Shares into fully paid-up equity shares as part of its rights issue. The company has received the necessary call monies from shareholders, allowing it to proceed with the conversion. The converted shares will be listed and traded accordingly.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has informed the Exchange regarding allotment of 2250 equity shares pursuant to exercise of ESOP options.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has updated its announcement regarding the appointment of Chief Information Officer (CIO) and Senior Management Personnel (SMP) of the company. The effective date of Mr. Ajit Manocha's appointment has been revised from August 10, 2026 to August 17, 2026 due to personal reasons.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd reported Q1 FY27 financial results, with revenues at INR384 crores, up 20% year-on-year, EBITDA at INR63.5 crores, up 10% year-on-year, and PAT at INR16.3 crores, up 55% year-on-year.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has published unaudited financial results for the quarter ended June 30, 2026, through a newspaper advertisement and on its website.

Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has submitted the Machine Readable copy of Financial results for the quarter ended June 30, 2026, as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.